The Clay Travis and Buck Sexton Show

Episode: Wellness Unmasked: Rethinking Mental Health
Featured Guest: Dr. Josef Witt-Doerring
Host: Dr. Nicole Saphier
Date: November 4, 2025

Brief Overview

This episode of "The Clay Travis and Buck Sexton Show" (Wellness Unmasked edition) joins Dr. Nicole Saphier and psychiatrist/former FDA medical officer Dr. Josef Witt-Doerring for a deep dive into the skyrocketing rates of antidepressant (SSRIs) prescriptions, especially in youth. The conversation covers the scientific, clinical, and social controversies about overmedication, long-term safety of SSRIs, challenges with mental health care, the fallacy of the "chemical imbalance" narrative, and what parents—and society—can do to better protect children and adolescents.

Key Discussion Points & Insights

1. Rising Tide of Mental Health Diagnoses and Prescriptions

• SSRIs and Antidepressant Usage: Prescriptions for kids, teens, and young adults have “skyrocketed” in recent decades, with Dr. Saphier noting a sharp increase during COVID-19 due to isolation, device usage, and broader diagnosis trends.

  • "Antidepressant prescriptions for kids, teenagers, and even young adults have skyrocketed. In some cases, these numbers have doubled." (Dr. Nicole Saphier, 02:38)

• Self-Harm and Aggression Trends: Alongside prescription rates, increases in self-harm and outbursts are acknowledged, sparking debate about whether the solution (pills) matches the true scale of the crisis.

2. Dr. Josef Witt-Doerring’s Unique Background and Perspective

• Credentials: Psychiatrist, former pharmaceutical industry worker (drug development), ex-FDA medical officer (psychiatric drug review), now CEO of the Taper Clinic.

• Philosophy: Strongly critical of overmedication and the clinical detachment from evidence; now specializes in helping patients come off psychiatric drugs.

  • "What else is unique about me is I worked in the pharmaceutical industry...and I also worked at the FDA as a medical officer in the division of psychiatry...that experience, along with working in academic medicine, really soured me on psychiatric medications." (Dr. Josef Witt-Doerring, 04:24)

3. The Evidence Gap and Shortcomings in Long-Term Efficacy Data

• Drugs Studied Short-Term Only: Clinical trials for antidepressants rarely last over a year, while most patients take them long-term.

• Adaptation and Diminished Returns: Dr. Witt-Doerring observed many patients for whom drugs worked briefly, then wore off—requiring dose increases or polypharmacy.

  • "We don't actually study any of these drugs longer than a year...it's kind of crazy that we don't really know whether they're effective past a year." (Dr. Josef Witt-Doerring, 05:43)
  • "Our brains are not designed to be on SSRIs for like decades at a time...for some people who get worse, it’s the drugs." (Dr. Josef Witt-Doerring, 07:19)

4. Debunking the ‘Chemical Imbalance’ Myth

• SSRI Mechanism, Not a Cure: SSRIs don’t “fix” a proven chemical imbalance in the brain, contrary to popular pharmaceutical messaging.

• No Evidence of Serotonin Deficit in Depression: Numerous studies over decades have found no clear difference in serotonin or its metabolites between depressed and non-depressed people.

  • "These drugs, they're not fixing a chemical imbalance...there has never been any evidence." (Dr. Josef Witt-Doerring, 09:07)
  • "We've been collecting cerebral spinal fluid, we've been doing autopsies...every time we've tried to look at this...we've never found it." (Dr. Josef Witt-Doerring, 11:23)
  • "That seems crazy to me that the narrative continues to be that you are fixing a chemical imbalance, yet you don't actually have objective evidence..." (Dr. Nicole Saphier, 12:40)

5. Dangerous Side Effects: Suicide and Aggression in Youth

• Black Box Warning: SSRIs come with well-documented suicide risk for young people (increase from 2% to 4% compared to placebo).

• Paradoxical Reactions: Numbing/‘blunting’ is the usual effect, but some people (especially children and teens) become agitated, aggressive, even violent or suicidal.

• Connection to Mass Violence: Though highly contentious and politicized, there are legal cases showing links between SSRIs and violent outbursts. Media/political forces often focus exclusively on gun access.

  • "For some people, if you put them on this drug, they can become acutely suicidal...it can actually push them into suicidal behavior or in even rarer cases, violence." (Dr. Josef Witt-Doerring, 13:25)
  • "Without a doubt, some people are being pushed into violence, homicide, and murder because of these medications." (Dr. Josef Witt-Doerring, 19:34)

6. Systems, Culture, and Youth Mental Health

• Societal Factors: Social media, isolation, decline in community/church involvement, and instant gratification contribute significantly to youth anxiety/depression.

• Overstretched Doctors and Quick Fixes: Growing patient load and corporate healthcare push physicians to diagnose and prescribe quickly rather than address root causes.

  • "You have to look at the family unit as a whole...social media use is massive...I think it's poisoning their minds." (Dr. Josef Witt-Doerring, 23:07)
  • "The Affordable Care Act...has put more pressure on a lot of people to see more patients, to spend less time...has resulted in rise in prescriptions because they don't have time to talk about the underlying drivers..." (Dr. Nicole Saphier, 25:51)
  • "We need to grab the steering wheel. We need to wrestle it away from corporate interests..." (Dr. Josef Witt-Doerring, 26:57)

7. Political Polarization and Pharma Influence

• SSRIs as a “Conservative Talking Point”: Criticizing overmedication is sometimes dismissed as a right-wing narrative, which stifles critical discussion and reform.

• Pharma Messaging and Stigma: Attempts to link criticism of overmedication to mental health stigma are described as “manufactured by the pharmaceutical industry” to expand markets.

  • "Anytime someone criticizes SSRIs...they want to characterize the person as having an anti-drug puritan agenda...that stuff came out of the medical affairs department of pharmaceutical companies." (Dr. Josef Witt-Doerring, 30:56)

8. Needed Policy Changes and Research Reforms

• Label Updates for Transparency: Warnings should clearly state lack of long-term studies and possible long-term harm—including withdrawal problems.

• Longer Clinical Trials: SSRIs need to be tested as long as they are typically prescribed—multiple years, like other chronic-use drugs.

  • "We need to update the labels...these drugs aren't studied long term...There's a proportion of people who have severe problems when they come off these medications." (Dr. Josef Witt-Doerring, 37:06)
  • "We need a trial that goes for at least two years. This is not impossible." (Dr. Josef Witt-Doerring, 37:44)

9. Gendered Patterns in Prescribing: Women and Menopause

• Hormones vs. Antidepressants: Noting that SSRIs are now commonly (and inappropriately) prescribed for menopausal symptoms (e.g., insomnia, hot flashes), rather than hormone therapy, despite the latter being clinically indicated.
  • "Every other woman who's perimenopausal is...being pressured into taking an SSRI when...just, you know, replace what is missing!" (Dr. Josef Witt-Doerring, 39:43)

10. Practical Guidance: Non-Drug Approaches & Tapering Off Antidepressants

Non-Drug Interventions (Best Evidence for Mild/Moderate Depression):

• 4 Main Focus Areas:
  • Relationship support (isolation, family, social connections)
  • Sense of meaning (career coaching, faith, community)
  • Physical health (nutrition, exercise, addressing comorbidities)
  • Sobriety/moderation (reducing alcohol, caffeine, recreational drugs)
  • "I've never met someone who was anxious or depressed who had those four things in line." (Dr. Josef Witt-Doerring, 43:01)

Coming Off SSRIs Safely:

• Gradual Taper: 5–10% dose reduction every 2–4 weeks, listening to one’s body, with special attention at the last dose.
• Precision: Suggests diluting medication to enable miniscule reductions at the withdrawal “endgame.”
  • "When they get to the lowest dose...we actually liquefy the medication...and it allows you to lower it down with such great precision." (Dr. Josef Witt-Doerring, 44:35)
• Always Involve a Doctor: Never stop antidepressants abruptly or without medical supervision.

Notable Quotes

• "Mental health and mental health treatment, it's not one size fits all. Antidepressants, they may be life changing for some, but they're not a cure all."
  – Dr. Nicole Saphier (47:01)

• "We are the doctors. We're the ones that work here. And there are different ways of working."
  – Dr. Josef Witt-Doerring (27:46)

• "I think a more nuanced discussion about the drugs and how they're not studied long term and how people get worse—I mean, that's not a partisan issue. Medicine shouldn't be like that. We just want honesty."
  – Dr. Josef Witt-Doerring (31:55)

Timestamps for Key Segments

• SSRIs Rise and Youth Mental Health: 02:38–04:17
• Dr. Witt-Doerring’s Background: 04:17–05:24
• Clinical Trial Evidence/Limitations: 05:43–08:18
• SSRIs: Chemical Imbalance Myth: 08:35–12:40
• Suicide, Violence, & SSRIs: 12:40–15:03, 18:53–21:27
• Societal/Cultural Root Causes, Family Focus: 23:03–25:51
• Healthcare System and Overprescribing: 25:51–29:47
• Politics and the Pharma Narrative: 29:47–32:56
• Policy Reform Recommendations: 36:47–38:16
• Women, Menopause, and Overprescribed SSRIs: 38:16–40:43
• Non-Drug Approaches & Tapering Protocols: 41:22–45:46
• Final Thoughts & Takeaways: 47:01–48:45

Memorable Moments

• Dr. Witt-Doerring’s candor about how drug companies manufacture narratives to expand their market and stifle dissent (31:00).
• His practical pointers for slow, precise medication tapering—down to liquefying tablets for microdose withdrawal (44:35).
• Dr. Saphier’s emphasis: "No shame in needing medication...but maybe short-term use should be the goal—not medication for life." (47:24)

Conclusion:

Tone: Forthright, evidence-driven, and deeply critical of system failures—while still compassionate toward those affected by mental illness.

Bottom Line:
SSRIs can provide short-term relief for some but are not well studied for long-term use, have potential for harm—especially in youth and women—and should not be the default answer to complex social, psychological, and physiological challenges. Open conversation, better evidence, non-drug interventions, and reform of healthcare incentives are crucial to truly address America’s mental health crisis.

Core message:
Mental health is not one size fits all. We must demand better evidence, acknowledge risks, destigmatize honest discussion, and focus more on root causes and sustainable, compassionate care.